New drug combo aims to shrink Hard-to-Treat tumors
Disease control
Not yet recruiting
This study tests a new drug called BC3195 combined with pembrolizumab in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.
Phase: PHASE1, PHASE2 • Sponsor: Biocity Biopharmaceutics Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC